IthaID: 810
Names and Sequences
Functionality: | Globin gene causative mutation | Pathogenicity: | Benign / Likely Benign |
---|---|---|---|
Common Name: | CD 6 GAG>AAG [Glu>Lys] | HGVS Name: | HBB:c.19G>A |
Hb Name: | HbC | Protein Info: | β 6(A3) Glu>Lys |
Context nucleotide sequence:
AGACACCATGGTGCATCTGACTCCT [G>A] AGGAGAAGTCTGCCGTTACTGCCCT (Strand: -)
Protein sequence:
MVHLTPKEKSAVTALWGKVNVDEVGGEALGRLLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSELHCDKLHVDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH
Also known as:
Comments: The substitution of Glutamic Acid (Glu) with Lysine (Lys) at the sixth position of the beta-globin chain induces an electrostatic interaction between positively charged β6-Lys groups and negatively charged adjacent molecules, leading to the decreased solubility of HbC in red cells. Due to this, crystal formation occurs, leading to increased blood viscosity and decreased red blood cell life span. Hemoglobin C trait (HbAC) is clinically silent. Hemoglobin C disease (HbCC) is also a mild disorder, and, while most people do not have any symptoms, others may experience mild hemolytic anemia, splenomegaly, and jaundice. Co-inheritance with HbS (HbCS) may cause severe complications, including vaso-occlusion crisis.
We follow the HGVS sequence variant nomenclature and IUPAC standards.
Phenotype
Hemoglobinopathy Group: | Structural Haemoglobinopathy |
---|---|
Hemoglobinopathy Subgroup: | β-chain variant |
Allele Phenotype: | N/A |
Stability: | N/A |
Oxygen Affinity: | N/A |
Associated Phenotypes: | Haemolytic anaemia [HP:0001878] |
Location
Chromosome: | 11 |
---|---|
Locus: | NG_000007.3 |
Locus Location: | 70613 |
Size: | 1 bp |
Located at: | β |
Specific Location: | Exon 1 |
Other details
Type of Mutation: | Point-Mutation(Substitution) |
---|---|
Effect on Gene/Protein Function: | Missense codons (Protein Structure) |
Ethnic Origin: | African |
Molecular mechanism: | Altered secondary structure |
Inheritance: | Recessive |
DNA Sequence Determined: | Yes |
HPLC
ID | Hb Variant | Gene | Instrument | Method | Area (%) | Ret Time (min) | Comments | ||
---|---|---|---|---|---|---|---|---|---|
14 | HbC | β | D-10 | Dual Kit Program | 82.5 | 4.82 | Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal. | [PDF] | |
32 | HbC | β | D-10 | HbA1c Program | 46.5 | 1.77 | Heterozygote | [PDF] | |
34 | HbC | β | D-10 | HbA1c Program | 89 | 1.76 | Homozygote; HbC homozygote does not lead to a thal intermedia but to a mild microcytic anemia. | [PDF] | |
258 | HbC | β | D-10 | Dual Kit Program | 26 | 4.7 | Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis. | [PDF] | |
265 | HbC | β | D-10 | Dual Kit Program | 32.3 | 4.7 | heterozygote | [PDF] | |
361 | HbC | β | D-10 | Dual Kit Program | 75.5 | 4.69 | HbC homozygous or compound heterozygous with beta zero thalassaemia. | [PDF] | |
413 | HbC | β | D-10 | Dual Kit Program | 79.3 | 4.69 | Homozygote. | [PDF] | |
488 | HbC | β | D-10 | Dual Kit Program | 29.6 | 4.7 | compounnd heterozygote for HbC and Hb Korle Bu | [PDF] | |
509 | HbC | β | D-10 | Dual Kit Program | 46.4 | 4.7 | Compound heterozygote for HbS and HbC | [PDF] | |
518 | HbC | β | D-10 | Dual Kit Program | 46.3 | 4.7 | Compound heterozygote for HbS and HbC | [PDF] | |
520 | HbC | β | D-10 | Dual Kit Program | 46.3 | 5.12 | Compound heterozygote for HbS and HbC | [PDF] | |
528 | HbC | β | D-10 | Dual Kit Program | 43.6 | 4.71 | Compound heterozygote for HbS and HbC | [PDF] | |
542 | HbC | β | D-10 | Dual Kit Program | 50.4 | 4.7 | Compound heterozygote for HbC and (delta-beta) zero thalassaemia. | [PDF] | |
546 | HbC | β | D-10 | Dual Kit Program | 59.4 | 4.7 | heterozygote | [PDF] | |
568 | HbC | β | D-10 | Dual Kit Program | 48.1 | 4.79 | Compound heterozygote for HbC and Hb O-Arab. | [PDF] | |
15 | HbC | β | VARIANT | β-thal Short Program | 84.2 | 5.09 | Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal. | [PDF] | |
259 | HbC | β | VARIANT | β-thal Short Program | 23.8 | 5.03 | Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis. | [PDF] | |
266 | HbC | β | VARIANT | β-thal Short Program | 37.6 | 4 | heterozygote | [PDF] | |
362 | HbC | β | VARIANT | β-thal Short Program | 79.4 | 5.06 | HbC homozygous or compound heterozygous with beta zero thalassaemia. | [PDF] | |
414 | HbC | β | VARIANT | β-thal Short Program | 82.3 | 5.06 | Homozygote. | [PDF] | |
489 | HbC | β | VARIANT | β-thal Short Program | 32 | 5.1 | compound heterozygote for HbC and Hb Korle Bu | [PDF] | |
492 | HbC | β | VARIANT | β-thal Short Program | 29.9 | 5.11 | Compound heterozygote for HbC and HbS. Recently transfused. | [PDF] | |
511 | HbC | β | VARIANT | β-thal Short Program | 45.8 | 5.1 | Compound heterozygote for HbC and HbS | [PDF] | |
530 | HbC | β | VARIANT | β-thal Short Program | 45.9 | 5.11 | Compound heterozygote for HbS and HbC | [PDF] | |
543 | HbC | β | VARIANT | β-thal Short Program | 61.1 | 5.1 | Compound heterozygote for HbC and (delta-beta) zero thalassaemia. | [PDF] | |
547 | HbC | β | VARIANT | β-thal Short Program | 62 | 5.1 | Compound heterozygote for HbC and beta-thalassaemia. | [PDF] | |
570 | HbC | β | VARIANT | β-thal Short Program | 47.7 | 5.12 | Compound heterozygote for HbC and Hb O-Arab. | [PDF] | |
16 | HbC | β | VARIANT II | β-thal Short Program | 86.8 | 5.16 | Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal. | [PDF] | |
17 | HbC | β | VARIANT II | Dual Kit Program | 82.3 | 4.42 | Compound heterozygous with CD 39. Could be confused with HbC homozygous. A2 level and hematological data suggest an associated beta-thal. | [PDF] | |
33 | HbC | β | VARIANT II | HbA1c Program | 37.1 | 2.11 | Heterozygote | [PDF] | |
35 | HbC | β | VARIANT II | HbA1c Program | 97 | 2.1 | Homozygote; HbC homozygote does not lead to a thal intermedia but to a mild microcytic anemia. | [PDF] | |
40 | HbC | β | VARIANT II | Dual Kit Program - HbA1c | 41.7 | 2.04 | heterozygote | [PDF] | |
260 | HbC | β | VARIANT II | β-thal Short Program | 25.1 | 5.11 | Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis. | [PDF] | |
261 | HbC | β | VARIANT II | Dual Kit Program | 24.9 | 4.438 | Hb AC + alpha thal. The presence of an alpha thalassemia reduces the level of HbC and increases the microcytosis. | [PDF] | |
267 | HbC | β | VARIANT II | β-thal Short Program | 33.9 | 5.17 | heterozygote | [PDF] | |
268 | HbC | β | VARIANT II | Dual Kit Program | 32.2 | 4.433 | heterozygote | [PDF] | |
363 | HbC | β | VARIANT II | β-thal Short Program | 18.5 | 4.86 | [PDF] | ||
364 | HbC | β | VARIANT II | Dual Kit Program | 74.8 | 4.41 | Homozygous. | [PDF] | |
415 | HbC | β | VARIANT II | β-thal Short Program | 85.4 | 5.13 | Homozygote. | [PDF] | |
416 | HbC | β | VARIANT II | Dual Kit Program | 78.9 | 4.416 | Homozygote. | [PDF] | |
513 | HbC | β | VARIANT II | Dual Kit Program | 42.7 | 4.422 | Compound heterozygote for HbC and HbS | [PDF] | |
522 | HbC | β | VARIANT II | Dual Kit Program | 43.2 | 4.431 | Compound heterozygote for HbS and HbC. | [PDF] | |
532 | HbC | β | VARIANT II | β-thal Short Program | 44.6 | 5.17 | Compound heterozygote for HbS and HbC | [PDF] | |
534 | HbC | β | VARIANT II | Dual Kit Program | 40.8 | 4.423 | Compound heterozygote for HbS and HbC | [PDF] | |
544 | HbC | β | VARIANT II | β-thal Short Program | 60.5 | 5.15 | Compound heterozygote for HbC and (delta-beta) zero thalassaemia. | [PDF] | |
545 | HbC | β | VARIANT II | Dual Kit Program | 50 | 4.414 | Compound heterozygote for HbC and (delta-beta) zero thalassaemia. | [PDF] | |
548 | HbC | β | VARIANT II | β-thal Short Program | 61.8 | 5.16 | Compound heterozygote for HbC and beta-thalassaemia. | [PDF] | |
549 | HbC | β | VARIANT II | Dual Kit Program | 59.3 | 4.422 | Compound heterozygote for HbC and beta-thalassaemia. | [PDF] | |
572 | HbC | β | VARIANT II | β-thal Short Program | 47.7 | 5.15 | Compound heterozygote for HbC and Hb O-Arab. | [PDF] | |
574 | HbC | β | VARIANT II | Dual Kit Program | 43.8 | 4.419 | Compound heterozygosity for HbC and Hb O Arab. | [PDF] |
In silico pathogenicity prediction
Sequence Viewer
Frequencies
Publications / Origin
- ITANO HA, NEEL JV, A new inherited abnormality of human hemoglobin., Proc. Natl. Acad. Sci. U.S.A. , 36(11), 613-7, 1950 PubMed
- NEEL JV, KAPLAN E, ZUELZER WW, Further studies on hemoglobin C. I. A description of three additional families segregating for hemoglobin C and sickle cell hemoglobin., Blood , 8(8), 724-34, 1953 PubMed
- RANNEY HM, LARSON DL, McCORMACK GH, Some clinical, biochemical and genetic observations on hemoglobin C., J. Clin. Invest. , 32(12), 1277-84, 1953 PubMed
- HUNT JA, INGRAM VM, A terminal peptide sequence of human haemoglobin?, Nature , 184(0), 640-1, 1959 PubMed
- SMITH EW, KREVANS JR, Clinical manifestations of hemoglobin C disorders., Bull Johns Hopkins Hosp , 104(1), 17-43, 1959 PubMed
- BAGLIONI C, INGRAM VM, Four adult haemoglobin types in one person., Nature , 189(0), 465-7, 1961 PubMed
- Fabry ME, Kaul DK, Raventos C, Baez S, Rieder R, Nagel RL, Some aspects of the pathophysiology of homozygous Hb CC erythrocytes., J. Clin. Invest. , 67(5), 1284-91, 1981 PubMed
- Boehm CD, Dowling CE, Antonarakis SE, Honig GR, Kazazian HH, Evidence supporting a single origin of the beta(C)-globin gene in blacks., Am. J. Hum. Genet. , 37(4), 771-7, 1985 PubMed
- Fischel-Ghodsian N, Hirsch PC, Bohlman MC, Rapid detection of the hemoglobin C mutation by allele-specific polymerase chain reaction., Am. J. Hum. Genet. , 47(6), 1023-4, 1990 PubMed
- Trabuchet G, Elion J, Dunda O, Lapouméroulie C, Ducrocq R, Nadifi S, Zohoun I, Chaventre A, Carnevale P, Nagel RL, Nucleotide sequence evidence of the unicentric origin of the beta C mutation in Africa., Hum. Genet. , 87(5), 597-601, 1991 PubMed
- Agarwal A, Guindo A, Cissoko Y, Taylor JG, Coulibaly D, Koné A, Kayentao K, Djimde A, Plowe CV, Doumbo O, Wellems TE, Diallo D, Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S., Blood , 96(7), 2358-63, 2000 PubMed
- Modiano D, Luoni G, Sirima BS, Simporé J, Verra F, Konaté A, Rastrelli E, Olivieri A, Calissano C, Paganotti GM, D'Urbano L, Sanou I, Sawadogo A, Modiano G, Coluzzi M, Haemoglobin C protects against clinical Plasmodium falciparum malaria., Nature , 414(6861), 305-8, 2001 PubMed
- Rihet P, Flori L, Tall F, Traore AS, Fumoux F, Hemoglobin C is associated with reduced Plasmodium falciparum parasitemia and low risk of mild malaria attack., Hum. Mol. Genet. , 13(1), 1-6, 2004 PubMed
- Modiano D, Bancone G, Ciminelli BM, Pompei F, Blot I, Simporé J, Modiano G, Haemoglobin S and haemoglobin C: 'quick but costly' versus 'slow but gratis' genetic adaptations to Plasmodium falciparum malaria., Hum. Mol. Genet. , 17(6), 789-99, 2008 PubMed
- Gouagna LC, Bancone G, Yao F, Yameogo B, Dabiré KR, Costantini C, Simporé J, Ouedraogo JB, Modiano D, Genetic variation in human HBB is associated with Plasmodium falciparum transmission., Nat. Genet. , 42(4), 328-31, 2010 PubMed
- Cyrklaff M, Sanchez CP, Kilian N, Bisseye C, Simpore J, Frischknecht F, Lanzer M, Hemoglobins S and C interfere with actin remodeling in Plasmodium falciparum-infected erythrocytes., Science , 334(6060), 1283-6, 2011 PubMed
A/A | Date | Curator(s) | Comments |
---|---|---|---|
1 | 2010-06-16 16:13:16 | The IthaGenes Curation Team | Created |
2 | 2013-10-15 17:00:14 | The IthaGenes Curation Team | Reviewed. |
3 | 2014-04-15 16:16:06 | The IthaGenes Curation Team | Reviewed. Added references. |
4 | 2014-04-15 16:25:49 | The IthaGenes Curation Team | Reviewed. Added ClinVar link; corrected common name. |
5 | 2014-04-15 19:17:44 | The IthaGenes Curation Team | Reviewed. Corrected strand. |
6 | 2024-02-23 08:41:54 | The IthaGenes Curation Team | Reviewed. Comment added |
7 | 2024-02-23 08:49:32 | The IthaGenes Curation Team | Reviewed. DNA info reviewed |